文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

延长俯卧位通气与插管COVID-19患者死亡率降低相关

Prolonged Prone Position Ventilation Is Associated With Reduced Mortality in Intubated COVID-19 Patients.
PubMed 文献 · Chest · 2022-11-04
一句话结论插管COVID-19患者接受延长(≥24 h)俯卧位通气较间歇(约16 h)俯卧位通气30天死亡风险降低(aHR 0.475)。

多中心回顾性队列研究纳入2020年3月11日至5月31日连续收治的插管COVID-19并接受俯卧位通气的患者,比较延长(≥24 h)与间歇(约16 h并每日仰卧)俯卧位策略。延长组157例、间歇组110例;延长组30天死亡风险(aHR 0.475;95%CI 0.336-0.670;P<.001)和90天死亡风险(aHR 0.638;95%CI 0.461-0.883;P=.006)均低于间歇组。在俯卧位时PaO2/FiO2≤150的患者中,延长俯卧位同样与30天(aHR 0.357;95%CI 0.213-0.597;P<.001)和90天(aHR 0.562;95%CI 0.357-0.884;P=.008)死亡率降低相关。延长组面部水肿发生率增加、俯卧位期间低血压发生率降低,总体俯卧位相关并发症无差异。

要点

  • 插管COVID-19患者延长(≥24 h)俯卧位通气较间歇(约16 h)俯卧位30天死亡风险降低(aHR 0.475;95%CI 0.336-0.670;P<.001)。
  • 90天死亡风险同样降低(aHR 0.638;95%CI 0.461-0.883;P=.006)。
  • 俯卧位时PaO2/FiO2≤150的患者中,延长俯卧位与30天(aHR 0.357;95%CI 0.213-0.597;P<.001)和90天(aHR 0.562;95%CI 0.357-0.884;P=.008)死亡率降低相关。
  • 延长俯卧位组俯卧-仰卧转换次数更少(中位数1次;95%CI 1-2 vs 3次;95%CI 1-4;P<.001)。
  • 总体俯卧位相关并发症无差异,但延长组面部水肿发生率增加、俯卧位期间低血压发生率降低。

适用人群与场景

  • 2020年3月11日至5月31日连续收治的插管COVID-19并接受俯卧位通气的患者
  • 延长俯卧位组157例,间歇俯卧位组110例

处置流程与药物剂量

  • 延长俯卧位策略:每次俯卧位持续24小时或以上
  • 间歇俯卧位策略:每次俯卧位约16小时,每日仰卧

研究设计与关键结果

  • 多中心回顾性队列研究,纳入连续收治的插管COVID-19并接受俯卧位通气的患者,延长俯卧位157例 vs 间歇俯卧位110例。
  • 主要终点30天全因死亡率:延长俯卧位组较间歇俯卧位组降低(aHR 0.475;95%CI 0.336-0.670;P<.001)。
  • 次要终点90天全因死亡率:延长俯卧位组较间歇俯卧位组降低(aHR 0.638;95%CI 0.461-0.883;P=.006)。
  • 俯卧位时PaO2/FiO2≤150的患者中,延长俯卧位组30天死亡率降低(aHR 0.357;95%CI 0.213-0.597;P<.001)。
  • 俯卧位时PaO2/FiO2≤150的患者中,延长俯卧位组90天死亡率降低(aHR 0.562;95%CI 0.357-0.884;P=.008)。
  • 延长俯卧位组俯卧-仰卧转换次数中位数1次(95%CI 1-2),间歇俯卧位组中位数3次(95%CI 1-4),P<.001。
  • 俯卧位策略与总体俯卧位相关并发症无关联,但延长俯卧位组面部水肿发生率增加、俯卧位期间低血压发生率降低。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究
  • 采用逆概率治疗加权(IPTW)控制潜在治疗选择偏倚
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,延长俯卧位通气是降低插管COVID-19患者死亡率的 safe、有效策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Prone position ventilation (PPV) is resource-intensive, yet the optimal strategy for PPV in intubated patients with COVID-19 is unclear.

RESEARCH QUESTION: Does a prolonged (24 or more h) PPV strategy improve mortality in intubated COVID-19 patients compared with intermittent (∼16 h with daily supination) PPV?

STUDY DESIGN AND METHODS: Multicenter, retrospective cohort study of consecutively admitted intubated COVID-19 patients treated with PPV between March 11 and May 31, 2020. The primary outcome was 30-day all-cause mortality. Secondary outcomes included 90-day all-cause mortality and prone-related complications. Inverse probability treatment weights (IPTW) were used to control for potential treatment selection bias.

RESULTS: Of the COVID-19 patients who received PPV, 157 underwent prolonged and 110 underwent intermittent PPV. Patients undergoing prolonged PPV had reduced 30-day (adjusted hazard ratio [aHR], 0.475; 95% CI, 0.336-0.670; P < .001) and 90-day (aHR, 0.638; 95% CI, 0.461-0.883; P = .006) mortality compared with intermittent PPV. In patients with Pao2/Fio2 ≤ 150 at the time of pronation, prolonged PPV was associated with reduced 30-day (aHR, 0.357; 95% CI, 0.213-0.597; P < .001) and 90-day mortality (aHR, 0.562; 95% CI, 0.357-0.884; P = .008). Patients treated with prolonged PPV underwent fewer pronation and supination events (median, 1; 95% CI, 1-2 vs 3; 95% CI, 1-4; P < .001). PPV strategy was not associated with overall PPV-related complications, although patients receiving prolonged PPV had increased rates of facial edema and lower rates of peri-proning hypotension.

INTERPRETATION: Among intubated COVID-19 patients who received PPV, prolonged PPV was associated with reduced mortality. Prolonged PPV was associated with fewer pronation and supination events and a small increase in rates of facial edema. These findings suggest that prolonged PPV is a safe, effective strategy for mortality reduction in intubated COVID-19 patients.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Okin D, Huang CY, Alba GA, et al. Prolonged Prone Position Ventilation Is Associated With Reduced Mortality in Intubated COVID-19 Patients. Chest. 2022. PMID: 36343687. doi:10.1016/j.chest.2022.10.034

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。